C

아이큐어

175250KOSDAQ기타 화학제품 제조업

49.0 / 100

Reference Date: 2026-07-24

Financial Score10.0 / 40
News Sentiment16.0 / 25
Momentum14.0 / 20
Disclosure9.0 / 15
AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Roughly flat over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

IQure, established in 2000, specializes in developing transdermal drug delivery systems (TDDS) and pharmaceutical patches, along with OEM/ODM cosmetics. Following the successful Phase III trial of its donepezil patch in 2021, the company has secured global licensing agreements with pharmaceutical giants like Menarini and Celltrion. It also operates an ISO-certified cosmetics manufacturing facility, focusing on skincare OEM/ODM.

Number of Employees

286people

Average Salary

10.7M KRW

Score Calculation Basis

Detailed Financial Score

PER
Industry Average 16.674.0Point
PBR
3.33Industry Average 1.060.0Point

3.1x industry avg (risky)

ROE
-82.73Industry Average 4.550.0Point

Well below industry avg

Debt Ratio
30.72Industry Average 8.130.0Point

3.8x industry avg (risky)

Trend 2023~20256.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲21.2% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲27.3% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -41.8% (declining, 3yr)

Detailed News Sentiment

5 totalPositive 2Neutral 3Negative 0Average Sentiment Score 64

Detailed Momentum

52-week position8.0Point

Near 52w high (100%, uptrend)

Current 2,170Won52-week high 2,17052-week low 1,805
1-month return3.0Point

1m 0% (flat)

Volume trend3.0Point

Volume surge

Detailed Disclosure

10 totalPositive 1Neutral 8Negative 1
  • Neutral주주총회소집공고2026-07-22
  • Neutral의결권대리행사권유참고서류2026-07-22
  • Neutral[기재정정]주주총회소집결의 (임시주주총회)2026-07-21
  • Neutral기타시장안내 (개선기간 종료에 따른 상장폐지 여부 결정 안내)2026-07-13
  • Neutral[기재정정]수시공시의무관련사항(공정공시) (도네페질 패치제 (제품명 : 도네시브 패치)의 라이센스 이전 계약해지)2026-07-02